ACT OLOPATADINE 0.1% SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

OLOPATADINE (OLOPATADINE HYDROCHLORIDE)

Mevcut itibaren:

TEVA CANADA LIMITED

ATC kodu:

S01GX09

INN (International Adı):

OLOPATADINE

Doz:

0.1%

Farmasötik formu:

SOLUTION

Kompozisyon:

OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1%

Uygulama yolu:

OPHTHALMIC

Paketteki üniteler:

5ML

Reçete türü:

Prescription

Terapötik alanı:

ANTIALLERGIC AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0132394001; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2021-07-30

Ürün özellikleri

_ _
ACT OLOPATADINE 0.1%
_ _
_Page 1_
PRODUCT MONOGRAPH
Pr
ACT_ _OLOPATADINE 0.1%
Olopatadine Hydrochloride Ophthalmic Solution, USP
Sterile
0.1% w/v olopatadine (as olopatadine hydrochloride)
Anti-allergy Agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Revision:
June 15, 2020
Submission Control Number: 239279
_ _
ACT OLOPATADINE 0.1%
_ _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
3
ADVERSE REACTIONS
...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
5
DOSAGE AND ADMINISTRATION
.......................................................................................
6
OVERDOSAGE
.........................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
6
STORAGE AND STABILITY
...................................................................................................
7
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................... 7
PART II: SCIENTIFIC INFORMATION
.................................................................................
9
PHARMACEUTICAL INFORMATION
...................................................................................
9
CLINICAL TRIALS
.